Recent advances in research on novel therapeutic mechanisms and strategies for exosome-based treatment of ischemic stroke.

Authors

Tairan Liu, Hanlin Cao, Xi Chen, Jiaxin Huang, Qiao Zhang, Mingze Sun, Wen Zeng, Yu Su

Published in

Frontiers in pharmacology. Volume 17. Pages 1930673. Epub Sep 22, 2026.

Abstract

Ischemic stroke (IS) accounts for over 80% of all stroke cases, featuring high disability, mortality, and recurrence rates. Conventional intravenous thrombolysis and mechanical thrombectomy are limited by narrow therapeutic windows, reperfusion injury, and the blood-brain barrier (BBB), which impedes the entry of neuroprotective agents into the brain parenchyma. Exosomes (Exos) are cell-secreted nanoscale extracellular vesicles (EVs) that carry miRNAs, proteins, and lipids, with low immunogenicity, BBB permeability, and ease of genetic modification, making them promising cell-free therapeutic agents for central nervous system (CNS) disorders. Exos alleviate cerebral ischemia-reperfusion injury by suppressing multiple forms of programmed cell death, oxidative stress, and neuroinflammation, repairing the BBB, and facilitating angiogenesis and neurogenesis. Genetic engineering, surface peptide modification, and drug loading further enhance brain-targeted exosomal enrichment. This review systematically summarises Exos biogenesis, multi-pathway neural repair mechanisms mediated by exosomal miRNAs, engineered delivery strategies, translational bottlenecks, and future research directions, aiming to provide theoretical support for the clinical transformation of Exos therapy for IS.

PMID:
42840637
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.